Nasdaq Stockholm AB has decided that the shares and subscription warrants (TO2) of CombiGene AB (publ) will be traded on Nasdaq First North Stockholm. The first day of trading is December 19, 2018.
The shares and the subscription rights will be traded with unchanged ticker (COMBI) and ISIN-Code (SE0006504593) for the share and (COMBI TO 2) and ISIN-code (SE0011616408) for the subscription rights.
No offer or issuing of new shares will be made in connection with the change from Spotlight Stock Market to Nasdaq First North Stockholm and the Company’s shareholders doesn’t need to take any actions in connection with the change.
“The change to Nasdaq First North will increase the awareness of CombiGene and attract a larger group of investors and accordingly it will give the company better access to both Swedish and International capital” says Jan Nilsson CEO of CombiGene
The Company has also produced a company description, which is available on the Company’s website, www.combigene.com
FNCA Sweden AB has been engaged as Certified Adviser for CombiGene AB on Nasdaq First North Stockholm